Recombinant herpes zoster vaccine - Beijing Health Guard Biotechnology
Latest Information Update: 19 Feb 2024
At a glance
- Originator Beijing Health Guard Biotechnology
- Class Synthetic vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes zoster
Most Recent Events
- 08 Feb 2024 Preclinical trials in Herpes zoster (Prevention) in China (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
- 08 Feb 2024 Beijing Health Guard Biotechnology plans to files an IND application for Herpes zoster (Prevention) in 2024 (Beijing Health Guard Biotechnology pipeline, February 2024)
- 08 Feb 2024 Beijing Health Guard Biotechnology plans a clinical trial for Herpes zoster (Prevention) (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)